Allogeneic T cell therapies depend on a single source of cells for the treatment of various patients. In this, the cells are collected from the donor for the creation of the master cell bank.
The Master cell bank is utilized as the source for the creation of cell populace that is further processed as per the demands of the specific treatment.
While the final cell populace is then utilized for the treatment of multiple patients. The allogeneic T cell therapies have various advantages such as the immediate readiness of
the cryopreserved batches for the patient therapy, standardization of the CAR-T cell, time for cell modifications, the collaboration of CAR T cells directed against the varied targets, redosing and lower costs using an industrialized procedure.
CAR-T and TCR-T therapies have already revolutionized blood cancer treatment. Researchers Duke-NUS Medical School are examining the capability of turning this approach for the treatment of coronavirus patients.
Scientists also informed that these immunotherapies might also beneficial in the treatment of SARS-CoV-2, the virus resulting in the current outbreak. Various companies are working on cell therapies for coronavirus.
AlloVir & Baylor College of Medicine are collaborated to produce an innovative therapy to treat the coronavirus.
Allogeneic T cell therapies Market: Drivers and Restraints:
Increasing cases of cancer and a rising variety of patients with failure response to varied treatments are witnessed to boosts the allogeneic T cell therapy market growth globally.
Additionally, increasing prevalence of cancer in geriatric & pediatric patients is projected to results in higher demand for an efficient and reliable treatment approach for the improvement of quality of patient’s lives.
Moreover, rising government activities for improving healthcare insurance framework and advancement in research & development activities for allogeneic T cell therapy is fueling the development of the allogeneic T cell therapy market.
Meanwhile, side effects related to the allogeneic T cell therapy may result in cytokine release syndrome & other neurological disorders including coma, seizures, delirium and hallucinations.
This factor is witnessed to restrain the allogeneic T cell therapy market growth.
Allogeneic T cell therapies Market: Overview
CD19 target antigens are witnessed to hold the dominant market share owing to the reality that end number of the companies were capable to receive their antigens approved & hence, commercialized them.
Additionally, the diagnostic centers segment held the largest share owing to the rising research and development activities and the utilization of engineered cell therapy in molecular diagnostics.
However, the acute lymphoblastic leukaemia has a dominant market share as allogeneic T Cell Therapy offers a therapeutic advantage for the patients who are suffering from the failure of conventional therapy.
Allogeneic T cell therapies Market: Regional Wise Outlook
Geographically, the allogeneic T cell therapies market is segregated into seven regions viz. Asia Pacific, North America & Latin America, Eastern Europe Western Europe, Japan, & the Middle East and Africa.
North America is expected to dominate the global allogeneic T cell therapies market followed by Europe & Asia Pacific. North America is expected to dominate the global allogeneic T cell therapies market due to the rising venture and research & development activities for the improvement of malignancy treatments in this region.
Meanwhile, Asia Pacific is witnessed to show remarkable developments over the gauge time frame owing to the expanding number of worldwide players teaming up just as assembling contracts for allogeneic T cell treatments with local players in the region.
Allogeneic T cell therapies Market: Key Market Participants
The key participants operating in the global Allogeneic T cell therapies market identified across the value chain include
- Tmunity Therapeutics
- Bellicum Pharmaceuticals Inc.
- Sorrento Therapeutics
- Bluebird Inc.
- Minerva Biotechnologies Corporation
- Kite Pharma
- CELGENE CORPORATION
- Fortress Biotech.
- Promab Biotechnologies
- Immune Therapeutics
- Ziopharm Oncology Inc
- Juno Therapeutics
- Novartis AG
- Eureka Therapeutics Inc.
- TILT Biotherapeutics
- Poseida Therapeutics Inc.
the major players are concentrating on the vital merger and securing to upgrade their share in the worldwide allogeneic T cell treatment market. For example, in April 2018, Pfizer, Inc. marked an arrangement with Allogene, to build up an investigational CAR-T cell treatment for rewarding malignant growth.
In January 2019, Novartis declared that they will procure CellforCure with the goal that they can grow their cell and quality treatment. This securing will assist the organization with making their Allogeneic T cell therapies Therapy Kymriah accessible for a huge number of patients worldwide and will likewise assist them with improving their assembling limit of cell and quality treatments.
The report covers exhaust analysis on:
- Allogeneic T cell therapies Market Segments
- Allogeneic T cell therapies Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain)
- Eastern Europe (Poland, Russia)
- Asia Pacific (India, China ASEAN, Australia & New Zealand)
- The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
- Detailed overview of the healthcare market
- Changing Allogeneic T cell therapies market dynamics in the industry
- Below the Allogeneic T cell therapies -depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Below the Allogeneic T cell therapies recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Allogeneic T cell therapies Market: Segmentation:
The global allogeneic T cell therapies market has been segregated based on antigen type, indication, end-user and geography.
By antigen type:
- CD 19
- CD 20
By indication :
- Diffuse Large B-Cell Lymphoma
- Multiple Myeloma
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Research Institutes
- Biotechnological & pharmaceutical organizations
- Diagnostic centers or labs
- Academics or educational centers
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.